The CEO of Locanabio shares details of 2 presentations the company is making this week at the 24th Annual Meeting of the American Society of Gene & Cell Therapy.
RNA-targeting gene therapy company Locanabio is debuting new data this week from 2 of their pipeline initiatives in neuromuscular and retinal diseases. The preclinical research highlights the company's novel approach to gene therapy, which involves delivering RNA-binding protein-based systems that correct dysfunctional RNA.
In an interview with GeneTherapyLive, Locanabio chief executive officer James Burns, PhD, shared details of the 2 presentations being shared at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, the first which includes preclinical in vivo data demonstrating the safety and efficacy of their novel adeno-associated virus serotype 9-delivered PUF RNA-binding protein system for the elimination of toxic CUG repeats in a mouse model of myotonic dystrophy type 1. The second presentation centers around the company's CRISPR/Cas13d gene therapy system for the treatment of Usher syndrome type 2.
Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy
June 18th 2025In honor of Alzheimer's & Brain Awareness Month, observed annually in June, we took a look back at recent news and insights in cell and gene therapy for Alzheimer disease and other dementias.
Eugenio Galli, MD, PhD, on Reexamining Frailty as a Barrier to CAR-T Treatment
June 16th 2025The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.